FeesSafety
Pluang+

Acrivon reports Q3 2026 results, expands into immunology with new JAK1 inhibitor and advances oncology pipeline.

Company Fundamentals
16 Nov 2026, 23:05 WIB
GlobeNewsWire
View Source
Bullish
Acrivon reports Q3 2026 results, expands into immunology with new JAK1 inhibitor and advances oncology pipeline.

Acrivon Therapeutics announced its Q3 2026 financial results, reporting a net loss of $17.9 million and holding $77.8 million in cash and investments to fund operations into late 2027. The company expanded its strategic focus by acquiring ACR-525, a Phase 2-ready, highly selective JAK1 inhibitor targeting immunology and inflammation, particularly eosinophilic esophagitis. Acrivon also highlighted promising clinical progress with its oncology pipeline, including positive early data for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor showing durable responses in lung and other cancers. Upcoming milestones include interim Phase 2b data for ACR-368 in endometrial cancer and IND filings for new candidates, positioning Acrivon for multiple value-driving events.

Acrivon Therapeutics' Q3 2026 financial results provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 17, 2026 03:31 WIB: out of 150 priced health-sector US stocks, 31 rose and 118 fell. Notable movers include RXRX at USD 2.90 with a 1-day change of -8.95% and 100% buy order activity, NTRA at USD 291.45 down 8.66% with 100% buy order activity, and ABEO at USD 2.61 up 7.85% with 60% buy order activity. Typical hold times range from 10 to 23 days on Pluang.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App